Acted like it's already bigger: a recent, in-motion company decision that only makes sense if the step-up is real
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近做出的、已经在行动中的、扩大公司业务的具体决定,并且该决定是基于已经存在的实际需求或业务,而非预期或市场预测。 在记录中,管理层提到了几个方面: 1. 与Abbott的SurVeil药物涂层球囊协议,这是之前宣布的,本季度确认了收入,但这是协议执行,不是新的扩大决定。 2. 收购Embolitech的血栓切除平台技术,这是本季度(2018年5月)完成的,支付了450万美元,并产生了IP R&D费用。管理层表示正在积极开发,并计划在2020年提交监管申请。这算是一个具体的扩大决定,但理由是什么?管理层提到血栓切除市场是4亿美元,但主要是市场机会,没有提到已有订单或客户。他们提到“我们正在执行一个非常激进的时间表”,但需求是预期的,不是已实现的。 3. 关于BTK和AV瘘管药物涂层球囊,管理层说正在推进,但也是基于预期。 4. 关于.014和.018球囊导管,已获得FDA批准,正在与潜在合作伙伴进行临床评估,但尚未有收入,目标是2019年产生收入。这也不是已实现的需求。 管理层还提到“我们继续投资于新产品管道”,但这是泛泛的。 关键点:是否有具体决定扩大产能、招聘、增加设施等?记录中没有提到招聘、产能扩张等。收购Embolitech是扩大产品线,但需求是市场预测,不是实际订单。管理层说“我们正在执行一个非常激进的时间表”,但这是基于技术潜力,不是现有业务。 因此,没有明确描述一个基于已实现需求的具体扩大决定。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| THS | TreeHouse Foods, Inc. | Q1 2023 | 2023-05-08 | B+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| ENLC | EnLink Midstream, LLC | Q4 2015 | 2016-02-17 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
JBHT · Q2 2022 → YESThe question is about whether management describes a specific recent decision the company made and is acting on that enlarges what they can do, justified by real existing demand, not hoped-for. YES In the transcript, management describes a concrete recent decision to expand capacity in multiple segments, already in motion and justified by real, current demand rather than forecasts. For Dedicated: "After selling 600 trucks in Q1, we sold slightly over 800 trucks in the second quarter... We've added nearly 2, 200 trucks to our business in the last 12 months... This unprecedented demand and growth for our highly engineered Fleet Service has put a strain on the organization, and the team has responded extremely well to the challenge." They are actively onboarding new business with strong backlog and pipeline, and will hold trades on roughly 4,000 tractors this year to support replacement and growth. For Intermodal: "Demand for our capacity continues to be greater than our ability to serve that demand... volumes by month for the quarter were up 4% in April, up 9% in May and up 10% in June on a year-over-year basis.
PRPO · Q3 2018 → YESThe question is: Does management describe at least one SPECIFIC DECISION THE COMPANY ITSELF RECENTLY MADE AND IS ALREADY ACTING ON — within roughly the last quarter or two — that visibly ENLARGES what...YES The transcript shows management describing a concrete, recent decision to expand the sales force by hiring top-notch individuals in Q3, resulting in a 10-member team that contributed to pathology services revenue growth of nearly 50% from the prior quarter. This is tied directly to real business activity: the sales team’s traction in securing new customers and converting pipeline, with management noting the growth is already occurring and expecting continued acceleration. Separately, they describe launching HemeScreen externally after internal validation, citing immediate real demand through numerous orders received from physicians just weeks after launch, which enlarges their offering and is presented as a meaningful step toward capturing 2019 revenue. Both examples meet the criteria as specific, already-in-motion enlargements justified by current, visible business rather than forecasts.
LOPE · Q2 2021 → YESThe question is about whether management describes a specific recent decision that enlarges the company's capabilities, based on real existing demand. YES Management describes GCE’s recent, concrete decision to expand its Orbis platform by signing contracts for new partners in Southern California and New York City markets and opening medical lab science programs with two additional partners. This enlarges the company’s off-campus classroom and laboratory capacity (currently 31 sites, targeting 40 by 2022). The decision is already in motion: one new site opened in spring 2021, two more in summer 2021, and further openings are scheduled for fall 2021 and 2022. Management ties this directly to real, already-arriving business—specifically, the 13.2% year 2021 enrollment growth at Orbis sites (up 19% in nursing) and the fact that partner institutions are actively seeking additional revenue streams because they derive 14% of revenues from GCE/Orbis programs and want to do more.